Compounding: medicine made to meet a need.

Compounding may help meet a person's medical need when approved products cannot, the US Food and Drug Administration (FDA) explains. From FDA compounding Q&A.

An allergy to a dye is an example in the FDA's explanation.

Ask why an FDA-approved, ready-made medicine would not meet your need.

What would the pharmacist change, and how would that help?

As of September 2026, compounded preparations do not have FDA approval. From FDA on compounded drug quality.

The FDA does not review their effect, safety or quality before they reach patients, as of September 2026. From FDA on compounded drug quality.

State pharmacy boards are the main bodies that check whether ordinary compounding pharmacies follow pharmacy rules. From FDA compounding Q&A.

Ask the pharmacy which state board checks its work. Also ask what checks it makes on the medicine it will prepare for you.

An active ingredient is the substance meant to give a medicine its effect.

Before that ingredient is made into medicine, it is called a bulk drug substance.

As of September 2026, US law limits which raw ingredients an ordinary compounding pharmacy may use. From FDA ingredient-list rules.

An ingredient with a US drug-quality standard has to satisfy that standard along with the pharmacy compounding standard.

A drug-quality standard is a written set of requirements for the ingredient.

Where no ingredient standard exists, an FDA-approved medicine must contain that ingredient.

If neither route applies, look to the FDA's official list: it must permit the raw ingredient for this kind of compounding.

These are legal requirements, not lab tests on your medicine.

BPC-157 and KPV are peptide ingredient names.

FDA records checked as of September 2026 found no US drug-quality standard for BPC-157 or KPV, no approved medicine containing either, and neither on the official list. From FDA's BPC ingredient review, FDA's KPV ingredient review.

Under those rules, an ordinary pharmacy could not lawfully compound BPC-157 or KPV from these raw ingredients, as of September 2026.

For any medicine made to order, ask the prescriber to explain whether the exact ingredient meets these requirements. Ask them to show you the written rule they rely on.

On the FDA page marked April 22, 2026, BPC-157 and KPV are listed as ingredients that groups had asked the FDA to allow for compounding. From FDA ingredient concerns.

Those groups withdrew, or took back, their requests.

As of September 2026, withdrawal does not give permission to compound those ingredients.

If someone says a pharmacy may now use an ingredient, ask them to show you the changed rule. Ask which ingredient it allows and when it took effect.